Table 3.
Overall survival among HNSCC patients by HPV markers, overall and by oropharynx, Eastern Massachusetts, 1999–2003*
| HPV16 markers | Overall (n=94) |
Oropharynx (n=45) |
||
|---|---|---|---|---|
| Death/Cases | HR (95% CI) | Death/Cases | HR (95% CI) | |
| HPV16 DNA (MPG) | ||||
| Negative | 13/35 | ref. | 5/15 | ref. |
| Positive | 23/59 | 1.0 (0.5–2.0) | 10/30 | 0.9 (0.3–2.9) |
| HPV16 DNA (SFPCR) | ||||
| Negative | 28/65 | ref. | 12/30 | ref. |
| Positive | 8/29 | 0.7 (0.3–1.5) | 3/15 | 0.4 (0.1–1.6) |
| HPV16 L1 (MS) | ||||
| Negative | 29/67 | ref. | 9/23 | ref. |
| Positive | 7/27 | 0.6 (0.2–1.5) | 6/22 | 0.5 (0.2–1.6) |
| HPV16 L1 (cLIA) | ||||
| Negative | 24/59 | ref. | 9/20 | ref. |
| Positive | 12/35 | 0.8 (0.4–1.6) | 6/25 | 0.3 (0.1–1.0) |
| HPV16 E6/E7 | ||||
| Negative | 31/64 | ref. | 11/19 | ref. |
| Either Positive | 5/30 | 0.2 (0.1–0.6) | 4/26 | 0.1 (0.02–0.3) |
| P16 IHC | ||||
| Negative | 25/60 | ref. | 8/18 | ref. |
| Positive | 11/34 | 0.6 (0.3–1.5) | 7/27 | 0.3 (0.1–1.1) |
| P16/E6/E7┼ | ||||
| P16−/E6/E7− | 24/56 | ref. | 8/15 | ref. |
| P16−/E6/E7+ | 1/4 | 0.4 (0.05–2.9) | 0/3 | - |
| P16+/E6/E7− | 7/8 | 3.1 (1.2–7.7) | 3/4 | 2.0 (0.4–10.0) |
| P16+/E6/E7+ | 4/26 | 0.3 (0.1–0.8) | 4/23 | 0.1 (0.02–0.4) |
| HPV 16 DNA (MPG)/E6/E7┼ | ||||
| DNA−/E6/E7− | 12/32 | Ref | 4/12 | ref. |
| DNA−/E6/E7+ | 1/3 | 0.4 (0.05–3.2) | 1/3 | 0.3 (0.02–3.4) |
| DNA+/E6/E7− | 19/32 | 1.5 (0.7–3.3) | 7/7 | 3.4 (0.6–18.1) |
| DNA+/E6/E7+ | 4/27 | 0.3 (0.1–0.9) | 3/23 | 0.1 (0.02–1.0) |
*
Analysis restricted to participants for whom data on each marker was available
┼
E6/E7− indicates both E6 and E7 seronegativity; E6/E7+ means either E6 or E7 seropositivity.